J. Pers. Med. 2014, 4(1), 52-64; doi:10.3390/jpm4010052
Commentary

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

1,* email, 2email, 3email, 4email, 5email, 5email and 6email
Received: 27 November 2013; in revised form: 15 February 2014 / Accepted: 27 February 2014 / Published: 7 March 2014
(This article belongs to the Special Issue Feature Paper 2013)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Registries evaluating un-randomized patients have provided valuable information with respect to a therapy’s utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.
Keywords: oncology; cancer; registry; immunotherapy; interleukin-2; melanoma; renal cell carcinoma
PDF Full-text Download PDF Full-Text [719 KB, uploaded 7 March 2014 10:36 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Kaufman, H.L.; Wong, M.K.; Daniels, G.A.; McDermott, D.F.; Aung, S.; Lowder, J.N.; Morse, M.A. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J. Pers. Med. 2014, 4, 52-64.

AMA Style

Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). Journal of Personalized Medicine. 2014; 4(1):52-64.

Chicago/Turabian Style

Kaufman, Howard L.; Wong, Michael K.; Daniels, Gregory A.; McDermott, David F.; Aung, Sandra; Lowder, James N.; Morse, Michael A. 2014. "The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)." J. Pers. Med. 4, no. 1: 52-64.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert